We are advancing a growing pipeline of oncology therapies and diagnostics to enable a theranostic approach to cancer treatment, with the promise of allowing patients to live longer, healthier lives.
We have hundreds of compounds in our Intellectual Property Portfolio.
Currently RāC℞ has multiple opportunities in the pipeline
Ax-101
An immune system modulatory drug, the First-in-Human trial showed no adverse effects and efficacy in multiple cancers.
Glutamine transport (ASCT2) inhibitors
V-9302 proven in-vivo by RāC℞ and 3rd parties in multiple human cancers. Currently pursuing a group of improved validated hits as ASCT2 inhibitors – weakening cancer cells and strengthening the immune system.